Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03319732 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS
A Phase 3 study of Multiple Sclerosis and Spasticity, Muscle, sponsored by RVL Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 323
- Enrollment target
- 1
- Study location
NCT03319732 is a Phase 3 study of Multiple Sclerosis and Spasticity, Muscle that has completed, run by RVL Pharmaceuticals. The registered enrollment target is 323 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03319732, a Phase 3 study of Multiple Sclerosis and Spasticity, Muscle, has completed, sponsored by RVL Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 323 participants
- Enrollment target
- 1
- Study location
Study Summary
Spasticity is a common complication in MS and occurs in up to 84% of patients. The main sign of spasticity is resistance to passive limb movement characterized by increased resistance to stretching, clonus, and exaggerated deep reflexes. Osmotica Pharmaceutical is currently developing arbaclofen extended-release tablets (AERT) for the treatment of spasticity in patients with MS.
Conditions Studied
Interventions
- DRUG Arbaclofen
Study Locations (1)
California
- Neuro Pain Medical Center - Fresno
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 323 participants |
| Start Date | 2018-04-03 |
| Est. Completion | 2020-06-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03319732
The ClinicalTrials.gov registry entry for NCT03319732 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 323 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (45% lower). The listed sponsor is RVL Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Arbaclofen is the first listed.
NCT03319732 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03319732 about?
NCT03319732 is a clinical study titled "A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS". Spasticity is a common complication in MS and occurs in up to 84% of patients. The main sign of spasticity is resistance to passive limb movement characterized by increased resistance to stretching, clonus, and exaggerated deep reflexes. Osmotica Pharmaceutical is currently developing arbaclofen ext...
What is the current status of trial NCT03319732?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 323 participants. The study started on 2018-04-03. Estimated completion is 2020-06-11.
What conditions does trial NCT03319732 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Spasticity, Muscle.
What interventions are being tested in trial NCT03319732?
The interventions under investigation include: Arbaclofen (DRUG).
Who is sponsoring clinical trial NCT03319732?
This trial is sponsored by RVL Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03319732 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
RECRUITING · Phase 3
-
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
RECRUITING · Phase 3
-
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.